

# The 2024 UN General Assembly High-Level Meeting on AMR Side Event

## “Global Action on AMR: Advancing Healthy Longevity and Sustainability under UHC”

### Background

Antimicrobial resistance (AMR), also known as the “silent pandemic,” already kills approximately 4.95 million people a year worldwide. Antimicrobial drugs are essential for the prevention of perioperative infections, and AMR could prevent society from enjoying safe and secure standard treatments such as cancer surgery. The impact of AMR has unfortunately spread to traditional infections, including drug-resistant tuberculosis and beyond infections. AMR now needs to be addressed as a structural challenge to the healthcare system and a cross-disease problem in an aging society, which requires strong leadership from the state and the international community.

This event will discuss Japan's past contributions, prospects, and expectations regarding AMR measures. Through the discussions, we will explore ways in which countries can work together to realize the UNGA's Political Declaration on AMR, a complex and multifaceted issue involving healthcare, agriculture, environment, economy, industrial development, security, trade, and others. In support of the themes of the high-level meeting, it will also touch on the essential role of civil society in the realization of the Political Declaration and national action plans.

### Overview

- **Date and time:** 14:00 – 16:00, 25 September 2024 (EDT)
- **Venue:** The Nippon Club (145 West 57th Street, New York, NY 10019) \*Invitation only
- **Host:** Health and Global Policy Institute (HGPI) and AMR Alliance Japan
- **Co-host:** Ministry of Health, Labour and Welfare, Japan
- **In partnership with:** AMR Multi-Stakeholder Partnership Platform, CARB-X, GARDP, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Japan Center for International Exchange (JCIE), and Japan Pharmaceutical Manufacturers Association (JPMA)
- **Supported by:** Nikkei FT Communicable Disease Conference
- **Language:** English



**Program** (titles omitted; in alphabetical order)

- 14:00 – 14:05     **Welcoming Remarks** \*pre-recorded video  
**Fumio Kishida** (Prime Minister of Japan)
- 14:05 – 14:15     **Opening Remarks**  
**Yasuhisa Shiozaki** (Chairman, Keisou Nippon Initiative Foundation / Member, Global Leaders Group on Antimicrobial Resistance / Chair, Executive Committee on Global Health and Human Security, Japan Center for International Exchange (JCIE))
- 14:15 – 14:20     **Introductory Explanation**  
**Yui Kohno** (Manager, Health and Global Policy Institute (HGPI) / AMR Alliance Japan)
- 14:20 – 15:20     **Roundtable Discussion “Contributions from Japan and Expectations towards Japan for Better AMR Policy in the World”**
- Speakers:**  
**James Anderson** (Executive Director of Global Health, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA))  
**Peter Beyer** (Deputy Executive Director, GARDP)  
**Vanessa Carter** (Chair, WHO Task Force of AMR Survivors / Executive Director, The AMR Narrative)  
**Christos Christou** (International President, Médecins Sans Frontières (MSF))  
**Hajime Inoue** (Assistant Minister for Global Health and Welfare, Minister’s Secretariat, Ministry of Health, Labour and Welfare, Government of Japan)  
**Norio Ohmagari** (Director, AMR Clinical Reference Center, National Center for Global Health and Medicine (NCGM))  
**Kevin Outterson** (Professor, Boston University / Executive Director, CARB-X)  
**Takuko Sawada** (Japan Pharmaceutical Manufacturers Association (JPMA) / Director and Vice Chairperson of the Board, Shionogi & Co., Ltd.)  
**Thanawat Tiensin** (AMR Multistakeholder Platform / Assistant Director-General and Chief Veterinarian, Food and Agriculture Organization of the United Nations (FAO) / Director, Animal Production and Health Division (NSA), FAO)  
**Anna Wechsberg** (International Director, Department of Health and Social Care, UK)
- Moderator:**  
**Ryoji Noritake** (Chair, Health and Global Policy Institute (HGPI))
- 15:20 – 15:30     **Closing Remarks**
- 15:30 – 16:00     **Networking**

**Resources**

Program handouts can be downloaded from the QR code below.



---

## Message from Dame Sally Davies

*AMR impacts all of us. Over **1.1million people died** from AMR in 2021, and by 2050, more than **39million people** will die. They could be any one of us, from anywhere in the world, although the burden falls the greatest in western sub-Saharan Africa, Tropical Latin America, high-income North America, Southeast Asia, and South Asia. That's why this High-Level Meeting is key to driving global action and I am grateful to HGPI and the AMR Alliance Japan for corraling ambition and action, and for the crucial demonstration of support from Fumio Kishida, Prime Minister of Japan.*

*The High-Level Meeting will put **access** at the heart of our action:*

- **Access** to antibiotics, which could save 92 million lives between 2025 and 2050.
- **Access** to sustainable financing – we need to leverage and make accessible the financing that is already out there in multilateral streams and development banks to fund National Action Plans on AMR.
- **Access** to education, scaling up some of the fantastic initiatives across the world, such as AMR art and drama clubs for schools in Tanzania.

*The first key step will be Member States agreeing to establish a new independent science panel on AMR, which we desperately need to assess the evidence that is out there and inform future targets and interventions. I hope the panel will be based at the UN Environment Programme HQ in Nairobi – so it can look at human, animal and environmental aspects of AMR, and be rooted where the burden of AMR is greatest.*

*I look forward to working with you all to deliver on our commitments and making progress to stop 39 million people dying by 2050. Everyone can play a personal and professional role in how they use antibiotics, consume meat, and raise awareness. **We can do it, together.***

Dame Sally Davies

Special Envoy on Antimicrobial Resistance for the United Kingdom

---

## Message Contributors Biography (titles omitted; in speaking order)

---

### Fumio Kishida (Prime Minister of Japan)



101st Prime Minister of Japan. Member of the House of Representatives; Liberal Democratic Party. He was elected 10 times (winning consecutive elections since his first election). In 1982, he graduated from the School of Law, Waseda University, and joined Long-Term Credit Bank of Japan, Ltd. He was elected to the House of Representatives for the first time in 1993, and served in a number of important positions, including as a member of the House Steering Committee (parliamentary proceedings officer), LDP Director General for Accounting, and Minister of State for Special Missions in the Cabinet Office, as well as Minister of Foreign Affairs from 2012, Minister of Defense in 2005, and Chairman of the Policy Research Council. He became the Prime Minister of Japan in the same year.

---

### Dame Sally Davies (UK Government Special Envoy on Antimicrobial Resistance)



Dame Sally Davies was appointed by the Prime Minister as the UK Government's Special Envoy on AMR in 2019. She is also the 40th Master of Trinity College, Cambridge University. Dame Sally was the Chief Medical Officer for England and Senior Medical Advisor to the UK Government from 2011-2019. She has become a leading figure in global health including serving as a member of the World Health Organization (WHO) Executive Board 2014-2016 and as co-convenor of the United Nations Inter-Agency Co-ordination Group (IACG) on Antimicrobial Resistance (AMR) reporting in 2019. In November 2020, Dame Sally was announced as a member of the new UN Global Leaders Group on AMR, serving alongside Heads of State, Ministers and prominent figures from around the world to advocate for action on AMR. In the 2020 New Year Honours, Dame Sally became the second woman (and the first outside the Royal family) to be appointed Dame Grand Cross of the Order of the Bath (GCB) for services to public health and research, having received her DBE in 2009.

Federal Institute of Intellectual Property in Bern, he negotiated bilateral free trade agreements and was responsible for the bilateral dialogue between Switzerland and China on intellectual property. During his time with the Ecologic Institute in Berlin, he was an adviser to the German Ministry of the Environment in international treaty negotiations and drafted the German law on CO2 emissions trading.

Most importantly, Peter was instrumental in setting up GARDP as well as the AMR Action Fund, with his wealth of knowledge and expertise.

---

\*The speakers above are providing a pre-recorded and pre-written message.

## Speakers Biography (titles omitted; in alphabetical order)

---

**James Anderson** (Executive Director of Global Health, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA))



James leads IFPMA's work spanning global health, including the innovative pharmaceutical industry's policy on pandemic preparedness, antimicrobial resistance (AMR), and global access to medicines and vaccines.

In his previous role as Head of Corporate Government Affairs at GlaxoSmithKline (GSK), James was responsible for GSK's strategic engagement with the UK Government. He also held positions in Government Affairs and Commercial at European and global levels and led their strategy and engagement on AMR. He was in the founding team of the AMR Action Fund and led the development of the 2016 Davos Declaration on AMR and the subsequent United Nations General Assembly Industry AMR Roadmap. He has advised on AMR policy development at the WHO, UN, EU Commission, and with national governments. James is Chair of the AMR Industry Alliance Board and Chair of the INTREPID Alliance Board. He has also served as the Vice-Chair of Health at Business at the OECD, and as a member of the UK Life Science Strategy Board. He has an MBA in Business from Harvard Business School as well as a Masters in Natural Sciences-Molecular and Genetic Pathology from Cambridge University.

---

**Peter Beyer** (Deputy Executive Director, GARDP)



Peter Beyer is a public health expert who joined GARDP from the World Health Organization (WHO), where he led the unit responsible for developing global initiatives to foster the development and access to new antimicrobial treatments. He was responsible for WHO's work on intellectual property and access to medicines, setting up the tripartite collaboration among the World Intellectual Property Organization (WIPO), the World Trade Organization (WTO) and WHO. He also provided technical assistance to countries to facilitate access to affordable HIV and hepatitis treatments. Peter chairs the Expert Advisory Group of the Medicines Patent Pool that assesses the terms and conditions of all proposed licence agreements.

Peter is a trained lawyer and was admitted to the bar in Berlin in 2002. He holds a PhD from the University of Freiburg, Germany on European environmental law and has extensive experience in international negotiations. As a Legal Advisor to the Swiss Federal Institute of Intellectual Property in Bern, he negotiated bilateral free trade agreements and was responsible for the bilateral dialogue between Switzerland and China on intellectual property. During his time with the Ecologic Institute in Berlin, he was an adviser to the German Ministry of the Environment in international treaty negotiations and drafted the German law on CO2 emissions trading.

Most importantly, Peter was instrumental in setting up GARDP as well as the AMR Action Fund, with his wealth of knowledge and expertise.

---

---

**Vanessa Carter** (Chair, WHO Taskforce of AMR Survivors / Executive Director, The AMR Narrative)

Vanessa became an AMR patient advocate in 2013 after surviving a serious car accident and a 10-year facial reconstruction that caused a highly-resistant MRSA infection on her face. She was a patient advisor to several organizations, including CIDRAP (USA), and served for three years as a member of the WHO Strategic Technical Advisory Group on AMR (STAG-AMR) between 2020 – 2023. She currently serves as a lay member to the Advisory Committee on Antimicrobial Prescribing, Resistance and Healthcare Associated Infection, UK (APRHAI) and is a civil society champion at the Africa CDC. Vanessa was the founder and currently serves as an Executive Director for The AMR Narrative. She is also currently Chair of the WHO Task Force of AMR Survivors.

---

**Christos Christou** (International President, Médecins Sans Frontières (MSF))

Dr Christos Christou is the International President of Médecins Sans Frontières. He joined MSF in 2002, working in search and rescue/migration and HIV/AIDS projects, and later in several conflict zones, including Sudan, South Sudan, Iraq, Cameroon, and Yemen, as a trauma surgeon. He was first General Secretary, then Vice-President and President of MSF Greece Board of Directors from 2005 until his election as International President in June 2019. Born in Trikala, a small town in central Greece, Dr Christou graduated from Aristotle University's medical school in Thessaloniki. He specialized in general and emergency surgery in the Surgical and Transplant Unit of Evangelismos Hospital in Athens. In 2013 he moved to London, working as a Senior Clinical Fellow in Colorectal surgery at King's College Hospital, and in 2018 as Consultant of Colorectal and Emergency Surgery at North Middlesex University Hospital. Dr Christou holds a Masters in International Health - Health Crisis Management from the Kapodestrian University of Athens and is a member of its faculty. He has a PhD in surgery and was awarded Fellow of the European Board of Surgery in Coloproctology. He is a member of the Advisory Committee for the CHH-Lancet Commission on Health, Conflict and Forced Displacement.

---

**Hajime Inoue** (Assistant Minister for Global Health and Welfare, Minister's Secretariat, Ministry of Health, Labour and Welfare, Government of Japan)



Dr. Hajime Inoue began his professional journey as a pediatric resident in Tokyo before dedicating himself to fieldwork as part of the Maternal and Child Health program in rural Philippines. Following post-graduate studies in public health, Dr. Inoue joined the Japanese Ministry of Health, Labour, and Welfare, where he amassed a wealth of technical expertise across various critical areas of global health, including UHC, Community Health, Health Emergency Response, Health Promotion, Population Ageing, Pharmaceutical Regulation, and Anti-Microbial Resistance (AMR). He has served as a Senior Advisor to the Director General of the WHO and as Special Representative for AMR, bringing his extensive political acumen to bear as the G20 and G7 Sherpa of WHO. Among his recent achievements are the development of a new financing mechanism, the Contingency Fund for Emergency at WHO, the management of Japan's largest national hospital as its Director-General, and his pivotal role in crafting the national response plan for COVID-19 as the chief technical officer of the cabinet secretariat. Dr. Inoue's recent appointments include serving as an advisor at the World Bank's Health, Nutrition, and Population program, and currently serving as Assistant Minister for Global Health at the Japanese Ministry of Health, Labor and Welfare. He holds a Medical Degree from Tottori University (Japan), a Master of International Health from the University of Tokyo (Japan), a Masters of Public Health from Harvard School of Public Health (USA), and a Doctor of Public Health from Teikyo University (Japan).

---

**Yui Kohno** (Manager, Health and Global Policy Institute (HGPI) / AMR Alliance Japan)



Ms. Yui Kohno is a graduate of the University of Sydney School of Public Health's Faculty of Medicine and Health in Australia. After obtaining a Master of Health Policy degree from the University of Sydney, Ms. Kohno joined Health and Global Policy Institute. There, she is responsible for research and analysis of national and global policy challenges within and beyond the fields of Antimicrobial Resistance (AMR) and vaccination. Her activities include planning and coordinating conferences for better policy dialogue and discussion and engaging in public relations, outreach, and advocacy activities.

---

**Ryoji Noritake** (Chair, Health and Global Policy Institute (HGPI))



Mr. Ryoji Noritake is the Chair of Health and Global Policy Institute (HGPI), a Tokyo-based independent and non-profit health policy think tank established in 2004. He also served as Asia-Pacific Lead for Project HOPE, a US-based medical humanitarian aid organization. Through HOPE and HGPI, he has led health system strengthening projects in the Asia-Pacific region and engaged in the US Navy's medical humanitarian projects. His focus is a multi-sectoral approach to health issues such as public-private partnerships and civil-military coordination. He was a member of the Tokyo Metropolitan Government's Policy Discussion Roundtable for Super Ageing Society (2018) and served as a Visiting Scholar at the National Graduate Institute for Policy Studies (2016-2020). He is currently serving as a member of World Dementia Council (WDC), the Salzburg Global Seminar's Advisory Council, Advisory Board Member of Elsevier Atlas, and the Dementia Innovation Alliance hosted by the Ministry of Economy, Trade and Industry (METI), Japan. He was awarded the 32nd Takemi Incentive Award in 2022. He is a graduate of Keio University's Faculty of Policy Management and holds a MSc in Medical Anthropology from the University of Amsterdam, the Netherlands.

---

**Norio Ohmagari** (Director, Disease Control and Prevention Center (DCC) of National Center for Global Health and Medicine (NCGM) / Director, AMR Clinical Reference Center / Director WHO Collaborating Center for Prevention, Preparedness and Response to Emerging Infectious Diseases)



Dr. Ohmagari has completed his clinical fellowship in Infectious Diseases at University of Texas-Houston. After serving as chief of the Division of Infectious Diseases at the Shizuoka Cancer Center, in 2011 Dr. Ohmagari moved to National Center for Global Health and Medicine (NCGM) which is one of six national medical centers in Japan with infectious diseases as main objective. At NCGM, Dr. Ohmagari has been acting as Director of the Disease Control and Prevention Center since 2012. In April 2017, he started a dual appointment as the Director of the AMR Clinical Reference Center and Director for the WHO Collaborating Centre for Prevention, Preparedness and Response to Emerging Infectious Diseases. From November 2023, he became the Deputy Director for Infection and Crisis Management and from April 2024 holds a dual appointment as Deputy Director for Disaster and First Aid.

---

**Kevin Outterson** (Professor, Boston University / Executive Director, CARB-X)



Kevin Outterson is a global thought leader on business models for antibiotic development and use. He is Professor of Law and N. Neil Pike Scholar of Health and Disability Law at Boston University School of Law, where he leads multi-disciplinary teams to solve global health issues. Professor Outterson is the Executive Director and Principal Investigator of CARB-X and a partner in DRIVE-AB.



---

**Takuko Sawada** (Japan Pharmaceutical Manufacturers Association (JPMA) / Director and Vice Chairperson of the Board, Shionogi & Co., Ltd.)



Following her graduation from Kyoto University, Ms. Takuko Sawada joined Shionogi & Co., Ltd. In 1977. Since then, she has served for over 30 years, leading a number of pharmaceutical development projects and corporate strategy planning. Ms. Sawada successively held various posts in the company including the senior vice president of Global Pharmaceutical Development Division, the senior vice president of Corporate Strategy Division and Corporate Planning Department, and board director. She has served in her current position since 2022.

---

**Yasuhisa Shiozaki** (Chairman, Keisou Nippon Initiative Foundation / Member, Global Leaders Group on Antimicrobial Resistance / Chair, Executive Committee on Global Health and Human Security, Japan Center for International Exchange (JCIE))



Yasuhisa Shiozaki is a former member of National Diet for 28 years and former Chief Cabinet Secretary (2006-2007), former Minister of Health, Labour and Welfare (2014-2017) of Japan. He has been a member of Global Leaders Group on Antimicrobial Resistance since 2020. He is also serving as Global Goodwill Ambassador of CEPI since 2022. Prior to his transition to politics, he had worked at the Bank of Japan. He graduated from the University of Tokyo and received his master's degree in public administration from the John F. Kennedy School of Government at Harvard University.

---

**Thanawat Tiensin** (AMR Multistakeholder Platform / Assistant Director-General and Chief Veterinarian, Food and Agriculture Organization of the United Nations (FAO) / Director, Animal Production and Health Division (NSA), FAO))



Thanawat Tiensin was appointed as Assistant Director-General effective August 1, 2024, Chief Veterinarian effective February 1, 2024, and Director of Animal Production and Health Division effective August 25, 2022. Additionally, he was assigned as Director Interim (Officer-in-Charge) at the Joint FAO/IAEA Center of Nuclear Techniques in Food and Agriculture, Vienna, Austria from November 2022 to July 2024. In 2018-2022, he served as Minister (Agriculture) and Permanent Representative of Thailand to the United Nations Agencies in Rome (FAO/IFAD/WFP). He served in several FAO governing bodies and committees, such as Chairperson of the Committee on World Food Security (CSF), Chairperson of the Global Soil Partnership (GSP), Vice Chair of the FAO Conference and the FAO Council, Vice Chair of the Committee of Agriculture (COAG) and COAG Sub-Committee on Livestock, member of FAO Finance Committee, etc. He was also appointed as the Advisory Committee of the UN Food Systems Summit. Mr. Tiensin, a national of Thailand, holds a Doctor of Philosophy (Ph.D.) and a Master of Sciences (M.Sc.) in Veterinary Epidemiology and Economics from Utrecht University, The Netherlands, and a Doctor of Veterinary Medicine (D.V.M.) from Kasetsart University, Thailand. He was a research fellow at Colorado State University in the United States.

---

**Anna Wechsberg** (International Director, Department of Health and Social Care, UK)



Anna joined DHSC as International Director in June 2020, at the height of the Covid19 pandemic. She leads the Department's relationship with WHO and is responsible for international bilateral relations including in the G7 and G20. She also oversees DHSC's UK Aid-funded Global Health Security programme, which helps protect global and UK health through investments in developing countries. Anna has spent the majority of her career working on international development and wider foreign policy, including as Policy Director for the Department for International Development where she led on global health and was responsible for a £1bn annual programme portfolio. She has represented the UK on the Boards of the World Bank and European Investment Bank, with experience working on foreign and development policy at the heart of government in No10, the Cabinet Office and HM Treasury.

---

## About Health and Global Policy Institute (HGPI)

Health and Global Policy Institute (HGPI) is a non-profit, independent, non-partisan health policy think tank established in 2004. As a neutral think-tank, HGPI involves stakeholders from wide-ranging fields of expertise to provide policy options to the public to create citizen-focused healthcare policies successfully. Looking to the future, HGPI produces novel ideas and values from a comprehensive perspective. It aims to realize a healthy and fair society while holding fast to its independence to avoid being bound to the specific interests of political parties and other organizations. HGPI intends for its policy options to be effective in Japan and the broader world. In this vein, the institute will continue to actively create policies for resolving global health challenges. HGPI's activities have received international recognition. It was ranked second in the "Domestic Health Policy Think Tanks" category and third in the "Global Health Policy Think Tanks" category in the Global Go To Think Tank Index Report presented by the University of Pennsylvania (as of January 2021, the most recent report).

## About AMR Alliance Japan

AMR Alliance Japan is an independent platform for the promotion of multisector discussion on AMR countermeasures. Since its establishment in November 2018, AMR Alliance Japan has worked with Alliance members and partner organizations to deepen policy debate around AMR. Current Members (in alphabetical order, as of September, 2024) are bioMérieux Japan Ltd., GlaxoSmithKline K.K., Himeji City, Japan Medical Association, Japan Pharmaceutical Association, Japan Pharmaceutical Manufacturers Association, Japanese Society for Pediatric Infectious Diseases, Japanese Society of Antimicrobials for Animals, Japanese Society of Chemotherapy, Japanese Society of Hospital Pharmacists, "Kodomo to Iryo" Project, Meiji Seika Pharma Co., Ltd., Merck & Co., Inc., Nippon Becton, Dickinson and Company, Ltd., Pfizer Japan Inc., Shimadzu Diagnostics Corporation, Shionogi & Co., Ltd., The Japanese Society for Medical Mycology, The Japanese Association for Infectious Diseases, The Japanese Society for Clinical Microbiology, The Japanese Society for Infection Prevention and Control, The Japanese Society of Pharmaceutical Health Care and Sciences, The Japanese Society of Therapeutic Drug Monitoring, The Pharmaceutical Society of Japan, Health and Global Policy Institute (HGPI) serves as Secretariat of the Alliance.

---

## Health and Global Policy Institute: Guidelines on Grants and Contributions

As an independent, non-profit, non-partisan private think tank, HGPI complies with the following guidelines relating to the receipt of grants and contributions.

### 1. Approval of Mission

The mission of HGPI is to improve the civic mind and individuals' well-being, and to foster a sustainable healthy community by shaping ideas and values, reaching out to global needs, and catalyzing society for impact. The activities of the Institute are supported by organizations and individuals who are in agreement with this mission.

### 2. Political Neutrality

HGPI is a private, non-profit corporation independent of the government. Moreover, we receive no support from any political party or other organization whose primary purpose is political activity of any nature.

### 3. Independence of Project Planning and Implementation

HGPI makes independent decisions on the course and content of its projects after gathering the opinions of a broad diversity of interested parties. The opinions of benefactors are solicited, but the Institute exercises independent judgment in determining whether any such opinions are reflected in its activities.

### 4. Diverse Sources of Funding

In order to secure its independence and neutrality, HGPI will seek to procure the funding necessary for its operation from a broad diversity of foundations, corporations, individuals, and other such sources. Moreover, as a general rule, funding for specific divisions and activities of the Institute will also be sought from multiple sources.

### 5. Exclusion of Promotional Activity

HGPI will not partake in any activity of which the primary objective is to promote or raise the image or awareness of the products, services or other such like of its benefactors.

### 6. Written Agreement

Submission of this document will be taken to represent the benefactor's written agreement with HGPI's compliance with the above guidelines.

---

---

**Host:****Co-host:**

---

**In partnership with:**

---

**Supported by:**